腎臟病診斷市場規模、佔有率和成長分析（按檢測類型、產品、最終用戶和地區分類）—產業預測，2026-2033年

預計到 2024 年，腎臟病診斷市場規模將達到 11.2 億美元，到 2025 年將達到 11.5 億美元，到 2033 年將達到 14.7 億美元，在預測期（2026-2033 年）內，複合年成長率為 3.1%。

由於人們對孕產婦健康和妊娠併發症的認知不斷提高，全球腎臟病診斷市場正經歷顯著成長。妊娠毒血症是一種影響產科的高血壓疾病，它推動了對精準早期診斷技術的需求，促使主要企業在該領域進行創新。醫療保健支出不斷成長、新興市場醫療基礎設施不斷完善以及產科護理中先進醫療技術的應用等因素，進一步推動了市場擴張。然而，先進診斷技術的高成本以及某些地區優質醫療資源的匱乏等挑戰，可能會阻礙市場發展。對新型生物標記和非侵入性診斷策略的持續研究，預計將進一步推動腎臟病診斷市場的發展。

腎臟病診斷市場促進因素

腎臟病診斷市場的發展動力源自於準確診斷孕婦子癇前症的複雜性。僅憑血壓升高並不能確診，凸顯了提高公眾意識的重要性。遺憾的是，許多女性對妊娠毒血症及其相關風險缺乏足夠的了解，導致孕期高血壓的識別延遲。這種認知不足限制了及時介入的可能性，因為疾病往往在症狀惡化之前難以察覺。由此對母親和新生兒帶來的健康風險十分嚴重，並導致嬰兒死亡率上升，因此迫切需要改進診斷方案。

限制腎臟病診斷市場的因素

由於妊娠高血壓疾病的診斷難度較高，僅憑血壓升高並不能確診，因此腎臟病診斷市場面臨嚴峻的挑戰。此外，許多孕婦缺乏對妊娠毒血症的認知，不了解其影響和相關風險。妊娠高血壓往往在出現更嚴重的症狀之前難以被發現，這限制了及時介入的機會。對妊娠毒血症的徵兆和潛在併發症缺乏了解，不僅會嚴重危害母親的健康，還會增加嬰兒上行風險，這成為市場成長的一大障礙。

腎臟病診斷市場趨勢

全球腎臟病診斷市場的一個顯著趨勢是，對孕婦早期風險評估的重視程度日益提高。這項轉變推動了基於生物標記的檢測方法的應用，這些方法利用與妊娠毒血症相關的特定生物標記。這些檢測能夠及時識別潛在病例，使醫護人員能夠實施早期療育並改善管理策略，最終改善母嬰結果。隨著醫療系統日益重視孕產婦健康和預防保健，先進診斷工具的整合體現了其致力於最大限度減少妊娠毒血症對妊娠結局不良影響的決心。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步

全球腎臟病診斷市場規模（按檢測類型分類）、複合年成長率（2026-2033 年）

• 血液檢查
• 尿液檢查
• 其他

全球腎臟病診斷市場規模（按產品分類）、複合年成長率（2026-2033 年）

• 裝置
• 消耗品

全球腎臟病診斷市場規模（按最終用戶分類）、複合年成長率（2026-2033 年）

• 醫院
• 專科診所
• 診斷中心
• 其他

全球腎臟病診斷市場規模（按地區分類）、複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Diabetomics Inc.（United States）
• DRG Instruments GmbH（Germany）
• F. Hoffmann-La Roche Ltd（Switzerland）
• PerkinElmer Inc.（United States）
• Siemens Healthineers AG（Germany）
• Thermo Fisher Scientific（United States）
• GE Healthcare（United States）
• Abbott Laboratories（United States）
• Acon Laboratories, Inc.（United States）
• Arkray, Inc.（Japan）
• Bio-Rad Laboratories, Inc.（United States）
• Cardinal Health（United States）
• Danaher Corporation（Beckman Coulter, Inc.）（United States）
• DIRUI Industrial Co., Ltd.（China）
• Metabolomic Diagnostics Ltd.（Ireland）
• Sera Prognostics（United States）
• Synlab Group（Germany）
• Microlife Corporation（Switzerland）
• Bayer AG（Germany）
• Progenity Inc.（United States）

結論與建議

Preeclampsia Diagnostics Market size was valued at USD 1.12 Billion in 2024 and is poised to grow from USD 1.15 Billion in 2025 to USD 1.47 Billion by 2033, growing at a CAGR of 3.1% during the forecast period (2026-2033).

The global market for preeclampsia diagnostics is experiencing significant growth driven by heightened awareness of maternal health and pregnancy complications. Preeclampsia, a hypertensive disorder impacting obstetrics, has spurred demand for precise and early diagnostic techniques, encouraging key players to innovate in this space. Factors such as increasing healthcare spending, enhancements in healthcare infrastructure in emerging markets, and the adoption of advanced medical technologies in obstetric care further bolster market expansion. Nonetheless, challenges like the high costs of sophisticated diagnostic methods and limited access to quality healthcare in specific regions could impede progress. Ongoing research into novel biomarkers and non-invasive diagnostic strategies is poised to propel the preeclampsia diagnostics market toward further advancements.

Top-down and bottom-up approaches were used to estimate and validate the size of the Preeclampsia Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Preeclampsia Diagnostics Market Segments Analysis

Global Preeclampsia Diagnostics Market is segmented by Test Type, Product, End-user and region. Based on Test Type, the market is segmented into Blood Tests, Urine Analysis and Others. Based on Product, the market is segmented into Instruments and Consumables. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market is driven by the complexities involved in accurately diagnosing this condition in expectant mothers. A mere spike in blood pressure does not provide a definitive diagnosis, which makes awareness crucial. Unfortunately, many women remain uninformed about preeclampsia and its associated risks, leading to a delay in recognizing hypertension during pregnancy. As symptoms often go unnoticed until they escalate, this gap in understanding limits the potential for timely intervention. The resulting health risks for mothers and their newborns can have severe consequences, contributing to higher rates of infant mortality and underscoring the urgent need for improved diagnostic solutions.

Restraints in the Preeclampsia Diagnostics Market

The preeclampsia diagnostics market faces significant challenges due to the complexity of accurately diagnosing this condition in pregnant women, as a mere rise in blood pressure does not provide definitive results. Additionally, a substantial number of pregnant individuals lack awareness about preeclampsia, its implications, and associated risks. Often, hypertension during pregnancy remains undetected until more severe symptoms develop, which restricts timely intervention opportunities. This gap in knowledge regarding the signs and potential complications of preeclampsia not only poses serious health risks to mothers but also increases the likelihood of higher infant mortality rates, presenting a critical barrier to market growth.

Market Trends of the Preeclampsia Diagnostics Market

The global preeclampsia diagnostics market is witnessing a noteworthy trend characterized by an enhanced focus on early risk assessment for expectant mothers. This shift is propelling the adoption of biomarker-based testing methods, which harness specific biological markers linked to preeclampsia. By facilitating the timely identification of potential cases, these tests empower healthcare professionals to administer early interventions and improve management strategies, ultimately fostering better outcomes for both mothers and their babies. As healthcare systems increasingly prioritize maternal health and preventative care, the integration of advanced diagnostic tools reflects a commitment to minimizing the adverse effects of preeclampsia on pregnancy outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Preeclampsia Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Urine Analysis
• Others

Global Preeclampsia Diagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
• Consumables

Global Preeclampsia Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others

Global Preeclampsia Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Product, End-user)
  • US
  • Canada
• Europe (Test Type, Product, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Product, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Product, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Product, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Diabetomics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DRG Instruments GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkray, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DIRUI Industrial Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Diagnostics Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sera Prognostics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synlab Group (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Microlife Corporation (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations